EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Concurrent immune checkpoint blockade for enhanced cancer immunotherapy utilizing engineered hybrid nanovesicles

Yuxuan Liu, Fuxu Yang, Zhimin Li, Ting Wang, Yeteng Mu, Yuxin Fan, Han Xue, Xiuli Hu, Xingang Guan, Hongxia Feng

Frontiers in Pharmacology · 11.11.2024 · 15

DOI: 10.3389/fphar.2024.1487940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.11.2024. Verfasst von Yuxuan Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The Affiliated Wenling Hospital of Taizhou University, Taizhou, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, demonstrating unprecedented efficacy against advanced cancers. However, their clinical applications are significantly hampered by low overall response rates. Dual blockade of two immune checkpoints represents a promising strategy to enhance immunotherapeutic efficacy. In this study, we developed hybrid cell membrane nanovesicles adorned with PD-1 and SIRPα receptors for combination immunotherapy in melanoma. Our hybrid nanovesicles (PD-1/SIRPα NVs) demonstrated high specificity to PD-L1 and CD47 ligands, facilitating the phagocytosis of melanoma cells by macrophages. In a melanoma mouse model, PD-1/SIRPα NVs significantly suppressed 77% of tumor growth and elicited a robust antitumor immune response for immunotherapy. In conclusion, our findings highlight the promising potential of PD-1/SIRPα NVs as novel and effective ICIs for cancer immunotherapy.

Schlagwörter

Stichwörter der Autor:innen

PD-1SIRPαcancer immunotherapycell membrane nanovesicleimmune checkpoint blockade

Autor:innen und Institutionen

  • Department of Dermatology, The Affiliated Wenling Hospital of Taizhou University, Taizhou, China.
  • College of Medical Technology, Beihua University, Jilin, China.
  • Medical School, Taizhou University, Taizhou, China.
  • Institute of Polymer Science and Engineering, School of Chemical Engineering, Hebei University of Technology, Tianjin, China.

Zitieren

APA

Liu, Y., Yang, F., Li, Z., Wang, T., Mu, Y., Fan, Y., Xue, H., Hu, X., Guan, X., & Feng, H. (2024). Concurrent immune checkpoint blockade for enhanced cancer immunotherapy utilizing engineered hybrid nanovesicles. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1487940

Vancouver

Liu Y, Yang F, Li Z, Wang T, Mu Y, Fan Y, et al. Concurrent immune checkpoint blockade for enhanced cancer immunotherapy utilizing engineered hybrid nanovesicles. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1487940

BibTeX
@article{Liu2024,
  author = {Liu, Yuxuan and Yang, Fuxu and Li, Zhimin and Wang, Ting and Mu, Yeteng and Fan, Yuxin and Xue, Han and Hu, Xiuli and Guan, Xingang and Feng, Hongxia},
  title = {Concurrent immune checkpoint blockade for enhanced cancer immunotherapy utilizing engineered hybrid nanovesicles},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1487940}
}
Kostenlos starten →